[BIO USA] Samsung Biologics to Expand Service Areas and Broaden Customer Base

Plans to Meet Diverse Customer Modality Needs
Pursuing Expansion of Business Portfolio to CRO Services

Samsung Biologics is set to expand both its service areas and its customer base. The company is pursuing an expansion of its business portfolio to include clinical research organization (CRO) services, and plans to continue its upward trend in contract wins.

Kevin Sharp, Vice President of Sales and Operations at Samsung Biologics Sales Center, held a meeting on the 18th (local time in the US) at the 2025 Bio International Convention (BIO USA) held in Boston, USA, explaining the company's competitiveness and sales strategy. Samsung Biologics

Kevin Sharp, Vice President of Sales and Operations at the Samsung Biologics Sales Center, held a meeting on the 18th (local time) at the 2025 Bio International Convention (BIO USA) in Boston, stating, "Samsung Biologics is proactively responding to market changes and expanding its service areas to meet customer needs for various modalities (therapeutic approaches). Through this, we plan to actively broaden our customer base from the existing global Top 20 pharmaceutical companies to the Top 40," he explained.

He said, "Centered around our CDO (contract development) Development Center and Bio Research Institute, we have secured CDMO capabilities for a variety of modalities, including monoclonal antibody (mAb) therapeutics, messenger RNA (mRNA), and antibody-drug conjugates (ADC). Furthermore, we are aiming to expand our business portfolio by securing core technologies in diverse fields, such as antibody-oligonucleotide conjugates (AOC) based on our capabilities in cell and gene therapy (CGT) with adeno-associated virus (AAV) and ADC."

Additionally, the company plans to secure production capabilities for ADC drug products (DP) and pre-filled syringes (PFS) by 2027.

Samsung Biologics is also pursuing an expansion of its business portfolio beyond CDMO to earlier-stage CRO services. Vice President Sharp stated, "On June 16, Samsung Biologics launched its first CRO service, 'Samsung Organoid,' a drug screening service using organoids. By collaborating with clients from the early stage of new drug candidate discovery, we aim to achieve an early 'lock-in' effect," he said.

The company also plans to continue its upward trend in contract wins, leveraging its production capacity and quality competitiveness. In the first half of this year alone, Samsung Biologics succeeded in winning a total of five new contracts, based on public disclosures.

Starting with a $1.41011 billion (approximately KRW 2.0747 trillion) contract with a European pharmaceutical company in January, the company has achieved balanced results across the US, Europe, and Asia. The total annual contract value for this year stands at $2.31904 billion (approximately KRW 3.355 trillion), already surpassing 60% of last year's annual contract value (approximately KRW 5.4035 trillion) in just about six months. Since its founding, the cumulative total contract value has reached $18.7 billion (approximately KRW 25.7 trillion).

The company also emphasized its commitment to securing core contract competitiveness based on the world's largest production capacity, quality, and a strong track record. He said, "With the recent completion of Plant 5, the first facility at the second Bio Campus in Songdo, Incheon, we have secured a total production capacity of 784,000 liters. This gives us overwhelming CAPA (production capacity) compared to our competitors."

He added, "We also possess overwhelming quality competitiveness, with a batch success rate of over 99% and 359 manufacturing approvals from global regulatory agencies."

Meanwhile, Samsung Biologics plans to pursue continued growth as a pure-play CDMO following the spin-off of its subsidiary Samsung Bioepis. According to Samsung Biologics, the fact that only 17 out of the global top 20 pharmaceutical companies are currently clients was due to conflicts of interest related to Samsung Bioepis.